APO Research
Talk to an analyst

APO RESEARCH · REPORT

Depression-MDD Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Depression-MDD Drugs Market Analysis and Forecast 2026-2032

31 December 2025198 pages

Choose your research edition.

Industry ResearchDepression-MDD Drugs Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Depression-MDD Drugs Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Depression-MDD Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Depression-MDD Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Depression-MDD Drugs Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Depression-MDD Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Depression-MDD Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Depression-MDD Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Depression-MDD Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Depression-MDD Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Depression-MDD Drugs include Merck, Eli Lilly, Pfizer, GlaxoSmithKline, AstraZeneca, Teva Pharmaceutical Industries, Reviva Pharmaceuticals Holdings, Janssen Pharmaceuticals and H. Lundbeck, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Depression-MDD Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Depression-MDD Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Depression-MDD Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Depression-MDD Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Depression-MDD Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Depression-MDD Drugs revenue, projected growth trends, production technology, application and end-user industry.

Depression-MDD Drugs Segment by Company

Merck

Eli Lilly

Pfizer

GlaxoSmithKline

AstraZeneca

Teva Pharmaceutical Industries

Reviva Pharmaceuticals Holdings

Janssen Pharmaceuticals

H. Lundbeck

Bristol-Myers Squibb

Depression-MDD Drugs Segment by Type

Selective Serotonin Reuptake Inhibitors,

Tricyclic Antidepressants

Atypical Antidepressants

Serotonin & Norepinephrine Reuptake Inhibitors

Depression-MDD Drugs Segment by Application

Online Pharmacy

Pharmacy

Hospital

Other

Depression-MDD Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Depression-MDD Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Depression-MDD Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Depression-MDD Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Depression-MDD Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Depression-MDD Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Depression-MDD Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Depression-MDD Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Selective Serotonin Reuptake Inhibitors, Major Player Table 3. Tricyclic Antidepressants Major Player Table 4. Atypical Antidepressants Major Player Table 5. Serotonin & Norepinephrine Reuptake Inhibitors Major Player Table 6. Global Depression-MDD Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Online Pharmacy Major Player Table 8. Pharmacy Major Player Table 9. Hospital Major Player Table 10. Other Major Player Table 11. Depression-MDD Drugs Industry Trends Table 12. Depression-MDD Drugs Industry Drivers Table 13. Depression-MDD Drugs Industry Opportunities and Challenges Table 14. Depression-MDD Drugs Industry Restraints Table 15. Global Depression-MDD Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Depression-MDD Drugs Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Depression-MDD Drugs Market Share by Region (2021-2026) Table 18. Global Depression-MDD Drugs Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Depression-MDD Drugs Market Share by Region (2027-2032) Table 20. Global Depression-MDD Drugs Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Depression-MDD Drugs Revenue Market Share by Players (2021-2026) Table 22. Global Depression-MDD Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Depression-MDD Drugs Key Players Headquarters & Area Served Table 24. Global Depression-MDD Drugs Players, Product Type & Application Table 25. Global Depression-MDD Drugs Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Depression-MDD Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Depression-MDD Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Depression-MDD Drugs Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Depression-MDD Drugs Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Depression-MDD Drugs Revenue Market Share by Type (2021-2026) Table 32. Global Depression-MDD Drugs Revenue Market Share by Type (2027-2032) Table 33. Global Depression-MDD Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Depression-MDD Drugs Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Depression-MDD Drugs Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Depression-MDD Drugs Revenue Market Share by Application (2021-2026) Table 37. Global Depression-MDD Drugs Revenue Market Share by Application (2027-2032) Table 38. Merck Company Information Table 39. Merck Business Overview Table 40. Merck Depression-MDD Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Merck Depression-MDD Drugs Product Portfolio Table 42. Merck Recent Development Table 43. Eli Lilly Company Information Table 44. Eli Lilly Business Overview Table 45. Eli Lilly Depression-MDD Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Eli Lilly Depression-MDD Drugs Product Portfolio Table 47. Eli Lilly Recent Development Table 48. Pfizer Company Information Table 49. Pfizer Business Overview Table 50. Pfizer Depression-MDD Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Pfizer Depression-MDD Drugs Product Portfolio Table 52. Pfizer Recent Development Table 53. GlaxoSmithKline Company Information Table 54. GlaxoSmithKline Business Overview Table 55. GlaxoSmithKline Depression-MDD Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. GlaxoSmithKline Depression-MDD Drugs Product Portfolio Table 57. GlaxoSmithKline Recent Development Table 58. AstraZeneca Company Information Table 59. AstraZeneca Business Overview Table 60. AstraZeneca Depression-MDD Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. AstraZeneca Depression-MDD Drugs Product Portfolio Table 62. AstraZeneca Recent Development Table 63. Teva Pharmaceutical Industries Company Information Table 64. Teva Pharmaceutical Industries Business Overview Table 65. Teva Pharmaceutical Industries Depression-MDD Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Teva Pharmaceutical Industries Depression-MDD Drugs Product Portfolio Table 67. Teva Pharmaceutical Industries Recent Development Table 68. Reviva Pharmaceuticals Holdings Company Information Table 69. Reviva Pharmaceuticals Holdings Business Overview Table 70. Reviva Pharmaceuticals Holdings Depression-MDD Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Reviva Pharmaceuticals Holdings Depression-MDD Drugs Product Portfolio Table 72. Reviva Pharmaceuticals Holdings Recent Development Table 73. Janssen Pharmaceuticals Company Information Table 74. Janssen Pharmaceuticals Business Overview Table 75. Janssen Pharmaceuticals Depression-MDD Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Janssen Pharmaceuticals Depression-MDD Drugs Product Portfolio Table 77. Janssen Pharmaceuticals Recent Development Table 78. H. Lundbeck Company Information Table 79. H. Lundbeck Business Overview Table 80. H. Lundbeck Depression-MDD Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. H. Lundbeck Depression-MDD Drugs Product Portfolio Table 82. H. Lundbeck Recent Development Table 83. Bristol-Myers Squibb Company Information Table 84. Bristol-Myers Squibb Business Overview Table 85. Bristol-Myers Squibb Depression-MDD Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Bristol-Myers Squibb Depression-MDD Drugs Product Portfolio Table 87. Bristol-Myers Squibb Recent Development Table 88. North America Depression-MDD Drugs Revenue by Type (2021-2026) & (US$ Million) Table 89. North America Depression-MDD Drugs Revenue by Type (2027-2032) & (US$ Million) Table 90. North America Depression-MDD Drugs Revenue by Application (2021-2026) & (US$ Million) Table 91. North America Depression-MDD Drugs Revenue by Application (2027-2032) & (US$ Million) Table 92. North America Depression-MDD Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 93. North America Depression-MDD Drugs Revenue by Country (2021-2026) & (US$ Million) Table 94. North America Depression-MDD Drugs Revenue by Country (US$ Million) & (2027-2032) Table 95. Europe Depression-MDD Drugs Revenue by Type (2021-2026) & (US$ Million) Table 96. Europe Depression-MDD Drugs Revenue by Type (2027-2032) & (US$ Million) Table 97. Europe Depression-MDD Drugs Revenue by Application (2021-2026) & (US$ Million) Table 98. Europe Depression-MDD Drugs Revenue by Application (2027-2032) & (US$ Million) Table 99. Europe Depression-MDD Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 100. Europe Depression-MDD Drugs Revenue by Country (2021-2026) & (US$ Million) Table 101. Europe Depression-MDD Drugs Revenue by Country (US$ Million) & (2027-2032) Table 102. China Depression-MDD Drugs Revenue by Type (2021-2026) & (US$ Million) Table 103. China Depression-MDD Drugs Revenue by Type (2027-2032) & (US$ Million) Table 104. China Depression-MDD Drugs Revenue by Application (2021-2026) & (US$ Million) Table 105. China Depression-MDD Drugs Revenue by Application (2027-2032) & (US$ Million) Table 106. Asia Depression-MDD Drugs Revenue by Type (2021-2026) & (US$ Million) Table 107. Asia Depression-MDD Drugs Revenue by Type (2027-2032) & (US$ Million) Table 108. Asia Depression-MDD Drugs Revenue by Application (2021-2026) & (US$ Million) Table 109. Asia Depression-MDD Drugs Revenue by Application (2027-2032) & (US$ Million) Table 110. Asia Depression-MDD Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 111. Asia Depression-MDD Drugs Revenue by Region (US$ Million) & (2021-2026) Table 112. Asia Depression-MDD Drugs Revenue by Region (US$ Million) & (2027-2032) Table 113. SAMEA Depression-MDD Drugs Revenue by Type (2021-2026) & (US$ Million) Table 114. SAMEA Depression-MDD Drugs Revenue by Type (2027-2032) & (US$ Million) Table 115. SAMEA Depression-MDD Drugs Revenue by Application (2021-2026) & (US$ Million) Table 116. SAMEA Depression-MDD Drugs Revenue by Application (2027-2032) & (US$ Million) Table 117. SAMEA Depression-MDD Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 118. SAMEA Depression-MDD Drugs Revenue by Country (2021-2026) & (US$ Million) Table 119. SAMEA Depression-MDD Drugs Revenue by Country (US$ Million) & (2027-2032) Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. Depression-MDD Drugs Image Figure 2. Global Depression-MDD Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Depression-MDD Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Selective Serotonin Reuptake Inhibitors, Image Figure 5. Tricyclic Antidepressants Image Figure 6. Atypical Antidepressants Image Figure 7. Serotonin & Norepinephrine Reuptake Inhibitors Image Figure 8. Global Depression-MDD Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Depression-MDD Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 10. Online Pharmacy Image Figure 11. Pharmacy Image Figure 12. Hospital Image Figure 13. Other Image Figure 14. Global Depression-MDD Drugs Market Size (US$ Million) & (2021-2032) Figure 15. Global Depression-MDD Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Depression-MDD Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Depression-MDD Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Depression-MDD Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Depression-MDD Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Depression-MDD Drugs Revenue Market Share by Type (2021-2032) Figure 22. Global Depression-MDD Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Depression-MDD Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Depression-MDD Drugs Revenue Market Share by Application (2021-2032) Figure 25. North America Depression-MDD Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Depression-MDD Drugs Revenue Share by Type (2021-2032) Figure 27. North America Depression-MDD Drugs Revenue Share by Application (2021-2032) Figure 28. North America Depression-MDD Drugs Revenue Share by Country (2021-2032) Figure 29. United States Depression-MDD Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Depression-MDD Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Depression-MDD Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Depression-MDD Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Depression-MDD Drugs Revenue Share by Type (2021-2032) Figure 34. Europe Depression-MDD Drugs Revenue Share by Application (2021-2032) Figure 35. Europe Depression-MDD Drugs Revenue Share by Country (2021-2032) Figure 36. Germany Depression-MDD Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Depression-MDD Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Depression-MDD Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Depression-MDD Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Depression-MDD Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Depression-MDD Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Depression-MDD Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Depression-MDD Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Depression-MDD Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Depression-MDD Drugs Revenue Share by Type (2021-2032) Figure 46. China Depression-MDD Drugs Revenue Share by Application (2021-2032) Figure 47. Asia Depression-MDD Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Depression-MDD Drugs Revenue Share by Type (2021-2032) Figure 49. Asia Depression-MDD Drugs Revenue Share by Application (2021-2032) Figure 50. Asia Depression-MDD Drugs Revenue Share by Region (2021-2032) Figure 51. Japan Depression-MDD Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Depression-MDD Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Depression-MDD Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Depression-MDD Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Depression-MDD Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Depression-MDD Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Depression-MDD Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Depression-MDD Drugs Revenue Share by Type (2021-2032) Figure 59. SAMEA Depression-MDD Drugs Revenue Share by Application (2021-2032) Figure 60. SAMEA Depression-MDD Drugs Revenue Share by Country (2021-2032) Figure 61. Brazil Depression-MDD Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Depression-MDD Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Depression-MDD Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Depression-MDD Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Depression-MDD Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Depression-MDD Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Depression-MDD Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Depression-MDD Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Depression-MDD Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Depression-MDD Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Depression-MDD Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Selective Serotonin Reuptake Inhibitors,
  • Tricyclic Antidepressants
  • Atypical Antidepressants
  • Serotonin & Norepinephrine Reuptake Inhibitors
Applications
  • Online Pharmacy
  • Pharmacy
  • Hospital
  • Other
Companies covered
  • Merck
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline
  • AstraZeneca
  • Teva Pharmaceutical Industries
  • Reviva Pharmaceuticals Holdings
  • Janssen Pharmaceuticals
  • H. Lundbeck
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Depression-MDD Drugs Market by Type
  3. 1.2.1 Global Depression-MDD Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Selective Serotonin Reuptake Inhibitors,
  5. 1.2.3 Tricyclic Antidepressants
  6. 1.2.4 Atypical Antidepressants
  7. 1.2.5 Serotonin & Norepinephrine Reuptake Inhibitors
  8. 1.3 Depression-MDD Drugs Market by Application
  9. 1.3.1 Global Depression-MDD Drugs Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Online Pharmacy
  11. 1.3.3 Pharmacy
  12. 1.3.4 Hospital
  13. 1.3.5 Other
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Depression-MDD Drugs Market Dynamics
  1. 2.1 Depression-MDD Drugs Industry Trends
  2. 2.2 Depression-MDD Drugs Industry Drivers
  3. 2.3 Depression-MDD Drugs Industry Opportunities and Challenges
  4. 2.4 Depression-MDD Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Depression-MDD Drugs Market Perspective (2021-2032)
  2. 3.2 Global Depression-MDD Drugs Growth Trends by Region
  3. 3.2.1 Global Depression-MDD Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Depression-MDD Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Depression-MDD Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Depression-MDD Drugs Revenue by Players
  2. 4.1.1 Global Depression-MDD Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Depression-MDD Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Depression-MDD Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Depression-MDD Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Depression-MDD Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Depression-MDD Drugs Players, Product Type & Application
  8. 4.5 Global Depression-MDD Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Depression-MDD Drugs Market CR5 and HHI
  11. 4.6.3 2025 Depression-MDD Drugs Tier 1, Tier 2, and Tier 3
5 Depression-MDD Drugs Market Size by Type
  1. 5.1 Global Depression-MDD Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Depression-MDD Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Depression-MDD Drugs Revenue Market Share by Type (2021-2032)
6 Depression-MDD Drugs Market Size by Application
  1. 6.1 Global Depression-MDD Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Depression-MDD Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Depression-MDD Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Merck
  2. 7.1.1 Merck Company Information
  3. 7.1.2 Merck Business Overview
  4. 7.1.3 Merck Depression-MDD Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Merck Depression-MDD Drugs Product Portfolio
  6. 7.1.5 Merck Recent Developments
  7. 7.2 Eli Lilly
  8. 7.2.1 Eli Lilly Company Information
  9. 7.2.2 Eli Lilly Business Overview
  10. 7.2.3 Eli Lilly Depression-MDD Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Eli Lilly Depression-MDD Drugs Product Portfolio
  12. 7.2.5 Eli Lilly Recent Developments
  13. 7.3 Pfizer
  14. 7.3.1 Pfizer Company Information
  15. 7.3.2 Pfizer Business Overview
  16. 7.3.3 Pfizer Depression-MDD Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Pfizer Depression-MDD Drugs Product Portfolio
  18. 7.3.5 Pfizer Recent Developments
  19. 7.4 GlaxoSmithKline
  20. 7.4.1 GlaxoSmithKline Company Information
  21. 7.4.2 GlaxoSmithKline Business Overview
  22. 7.4.3 GlaxoSmithKline Depression-MDD Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 GlaxoSmithKline Depression-MDD Drugs Product Portfolio
  24. 7.4.5 GlaxoSmithKline Recent Developments
  25. 7.5 AstraZeneca
  26. 7.5.1 AstraZeneca Company Information
  27. 7.5.2 AstraZeneca Business Overview
  28. 7.5.3 AstraZeneca Depression-MDD Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 AstraZeneca Depression-MDD Drugs Product Portfolio
  30. 7.5.5 AstraZeneca Recent Developments
  31. 7.6 Teva Pharmaceutical Industries
  32. 7.6.1 Teva Pharmaceutical Industries Company Information
  33. 7.6.2 Teva Pharmaceutical Industries Business Overview
  34. 7.6.3 Teva Pharmaceutical Industries Depression-MDD Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Teva Pharmaceutical Industries Depression-MDD Drugs Product Portfolio
  36. 7.6.5 Teva Pharmaceutical Industries Recent Developments
  37. 7.7 Reviva Pharmaceuticals Holdings
  38. 7.7.1 Reviva Pharmaceuticals Holdings Company Information
  39. 7.7.2 Reviva Pharmaceuticals Holdings Business Overview
  40. 7.7.3 Reviva Pharmaceuticals Holdings Depression-MDD Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Reviva Pharmaceuticals Holdings Depression-MDD Drugs Product Portfolio
  42. 7.7.5 Reviva Pharmaceuticals Holdings Recent Developments
  43. 7.8 Janssen Pharmaceuticals
  44. 7.8.1 Janssen Pharmaceuticals Company Information
  45. 7.8.2 Janssen Pharmaceuticals Business Overview
  46. 7.8.3 Janssen Pharmaceuticals Depression-MDD Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Janssen Pharmaceuticals Depression-MDD Drugs Product Portfolio
  48. 7.8.5 Janssen Pharmaceuticals Recent Developments
  49. 7.9 H. Lundbeck
  50. 7.9.1 H. Lundbeck Company Information
  51. 7.9.2 H. Lundbeck Business Overview
  52. 7.9.3 H. Lundbeck Depression-MDD Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 H. Lundbeck Depression-MDD Drugs Product Portfolio
  54. 7.9.5 H. Lundbeck Recent Developments
  55. 7.10 Bristol-Myers Squibb
  56. 7.10.1 Bristol-Myers Squibb Company Information
  57. 7.10.2 Bristol-Myers Squibb Business Overview
  58. 7.10.3 Bristol-Myers Squibb Depression-MDD Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Bristol-Myers Squibb Depression-MDD Drugs Product Portfolio
  60. 7.10.5 Bristol-Myers Squibb Recent Developments
8 North America
  1. 8.1 North America Depression-MDD Drugs Revenue (2021-2032)
  2. 8.2 North America Depression-MDD Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Depression-MDD Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Depression-MDD Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Depression-MDD Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Depression-MDD Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Depression-MDD Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Depression-MDD Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Depression-MDD Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Depression-MDD Drugs Revenue by Country
  11. 8.6.1 North America Depression-MDD Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Depression-MDD Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Depression-MDD Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Depression-MDD Drugs Revenue (2021-2032)
  2. 9.2 Europe Depression-MDD Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Depression-MDD Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Depression-MDD Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Depression-MDD Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Depression-MDD Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Depression-MDD Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Depression-MDD Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Depression-MDD Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Depression-MDD Drugs Revenue by Country
  11. 9.6.1 Europe Depression-MDD Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Depression-MDD Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Depression-MDD Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Depression-MDD Drugs Revenue (2021-2032)
  2. 10.2 China Depression-MDD Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Depression-MDD Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Depression-MDD Drugs Revenue by Type (2027-2032)
  5. 10.3 China Depression-MDD Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Depression-MDD Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Depression-MDD Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Depression-MDD Drugs Revenue by Application (2027-2032)
  9. 10.5 China Depression-MDD Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Depression-MDD Drugs Revenue (2021-2032)
  2. 11.2 Asia Depression-MDD Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Depression-MDD Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Depression-MDD Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Depression-MDD Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Depression-MDD Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Depression-MDD Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Depression-MDD Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Depression-MDD Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Depression-MDD Drugs Revenue by Country
  11. 11.6.1 Asia Depression-MDD Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Depression-MDD Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Depression-MDD Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Depression-MDD Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Depression-MDD Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Depression-MDD Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Depression-MDD Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Depression-MDD Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Depression-MDD Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Depression-MDD Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Depression-MDD Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Depression-MDD Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Depression-MDD Drugs Revenue by Country
  11. 12.6.1 SAMEA Depression-MDD Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Depression-MDD Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Depression-MDD Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst